Please enable JavaScript to continue using this application.

Compare $CCCC vs $USBC | Chartloom

Compare

$CCCC vs $USBC

C4 Therapeutics, Inc · USBC Inc

CCCC

C4 Therapeutics, Inc

USBC

USBC Inc

Compare $CCCC vs $USBC

Comparing C4 Therapeutics, Inc and USBC Inc

CCCCC4 Therapeutics, Inc

USBCUSBC Inc

CCCCC4 Therapeutics, Inc

Market cap

$349M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.01x

Rev growth (TTM)

2.3%

YTD performance

63.7%

52W performance

41.7%

FCF yield

-24.4%

USBCUSBC Inc

Market cap

$198M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-22.2%

52W performance

-51.9%

FCF yield

-11.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CCCC

USBC

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

USBC

USBC Inc

Market Cap

CCCC$349M

USBC$198M

Enterprise Value

CCCC$271M

USBC$210M

Price

CCCC$3.16

USBC$0.51

P/E Ratio

CCCCN/A

USBCN/A

P/S Ratio

CCCC9.97x

USBC0.00x

EV/Sales

CCCC7.73x

USBC0.00x

EV/EBITDA

CCCC0.00x

USBC0.00x

P/B Ratio

CCCC1.47x

USBC4.46x

P/FCF Ratio

CCCCN/A

USBCN/A

EV/FCF

CCCC-3.17x

USBC-9.14x

PEG Ratio

CCCCN/A

USBCN/A

Forward P/E (NTM)

CCCCN/A

USBCN/A

Forward P/S (NTM)

CCCC15.01x

USBCN/A

Revenue (TTM)

CCCC$35M

USBC$0

Revenue Growth (YoY)

CCCC2.3%

USBCN/A

Forward Rev Growth

CCCC-15.9%

USBC0.0%

Gross Margin (TTM)

CCCC0.0%

USBC0.0%

Operating Margin (TTM)

CCCC0.0%

USBC0.0%

EBITDA Margin (TTM)

CCCC-283.8%

USBC0.0%

Net Margin (TTM)

CCCC-289.4%

USBC0.0%

FCF Margin (TTM)

CCCC-243.7%

USBCN/A

Net Income (TTM)

CCCC$-101M

USBC$-86M

FCF (TTM)

CCCC$-85M

USBC$-23M

EPS (TTM)

CCCC-$0.78

USBC-$0.22

ROE (TTM)

CCCC-4545.0%

USBC-12093.0%

ROA (TTM)

CCCC-3090.0%

USBC-9639.0%

ROIC (TTM)

CCCC-4545.0%

USBC-11297.0%

Cash

CCCC$79M

USBC$3M

Debt

CCCC$0

USBC$15M

Net Cash/Debt

CCCC$79M

USBC$-12M

Current Ratio (TTM)

CCCC5.45x

USBC0.23x

Quick Ratio (TTM)

CCCC5.29x

USBC0.20x

Debt/Equity (TTM)

CCCC0.00x

USBC0.32x

Debt/Assets (TTM)

CCCC0.0%

USBC0.0%

Interest Coverage (TTM)

CCCCN/A

USBCN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

USBC0.00x

Beta

CCCC3.16

USBC2.77

52W Performance

CCCC41.7%

USBC-51.9%

YTD Performance

CCCC63.7%

USBC-22.2%

% from 52W High

CCCC-38.9%

USBC-60.5%

% from 52W Low

CCCC87.0%

USBC78.7%

Asset Turnover (TTM)

CCCC0.11x

USBC0.00x

FCF Yield (TTM)

CCCC-24.4%

USBC-11.6%

Earnings Yield (TTM)

CCCC-29.0%

USBC-43.5%

Dividend Yield (TTM)

CCCCN/A

USBCN/A

Rule of 40

CCCC-241.4

USBC0.0

EV/GP/RG

CCCCN/A

USBCN/A

Ticker research

View CCCC research View USBC research

Metric	CCCC C4 Therapeutics, Inc	USBC USBC Inc
Market & Valuation
Market Cap	$349M	$198M
Enterprise Value	$271M	$210M
Price	$3.16	$0.51
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	0.00x
EV/Sales	7.73x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	4.46x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-9.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	2.3%	N/A
Forward Rev Growth	-15.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	0.0%
Net Margin (TTM)	-289.4%	0.0%
FCF Margin (TTM)	-243.7%	N/A
Net Income (TTM)	$-101M	$-86M
FCF (TTM)	$-85M	$-23M
EPS (TTM)	-$0.78	-$0.22
ROE (TTM)	-4545.0%	-12093.0%
ROA (TTM)	-3090.0%	-9639.0%
ROIC (TTM)	-4545.0%	-11297.0%
Financial Health
Cash	$79M	$3M
Debt	$0	$15M
Net Cash/Debt	$79M	$-12M
Current Ratio (TTM)	5.45x	0.23x
Quick Ratio (TTM)	5.29x	0.20x
Debt/Equity (TTM)	0.00x	0.32x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	2.77
52W Performance	41.7%	-51.9%
YTD Performance	63.7%	-22.2%
% from 52W High	-38.9%	-60.5%
% from 52W Low	87.0%	78.7%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-24.4%	-11.6%
Earnings Yield (TTM)	-29.0%	-43.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View USBC research

Valuation

P/S Ratio

USBC

0.00x

CCCC

9.97x

EV/FCF

USBC

-9.14x

CCCC

-3.17x

Growth & revenue

Revenue Growth TTM

CCCC

2.3%

Forward Revenue Growth

USBC

0.0%

CCCC

-15.9%

Profitability & performance

Gross Margin

CCCC

0.0%

USBC

0.0%

ROE

CCCC

-4545.0%

USBC

-12093.0%

FCF Yield %

USBC

-11.6%

CCCC

-24.4%

52-Week Performance

CCCC

41.7%

USBC

-51.9%

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

USBC

USBC Inc

Market Cap

CCCC$349M

USBC$198M

Enterprise Value

CCCC$271M

USBC$210M

Price

CCCC$3.16

USBC$0.51

P/E Ratio

CCCCN/A

USBCN/A

P/S Ratio

CCCC9.97x

USBC0.00x

EV/Sales

CCCC7.73x

USBC0.00x

EV/EBITDA

CCCC0.00x

USBC0.00x

P/B Ratio

CCCC1.47x

USBC4.46x

P/FCF Ratio

CCCCN/A

USBCN/A

EV/FCF

CCCC-3.17x

USBC-9.14x

PEG Ratio

CCCCN/A

USBCN/A

Forward P/E (NTM)

CCCCN/A

USBCN/A

Forward P/S (NTM)

CCCC15.01x

USBCN/A

Revenue (TTM)

CCCC$35M

USBC$0

Revenue Growth (YoY)

CCCC2.3%

USBCN/A

Forward Rev Growth

CCCC-15.9%

USBC0.0%

Gross Margin (TTM)

CCCC0.0%

USBC0.0%

Operating Margin (TTM)

CCCC0.0%

USBC0.0%

EBITDA Margin (TTM)

CCCC-283.8%

USBC0.0%

Net Margin (TTM)

CCCC-289.4%

USBC0.0%

FCF Margin (TTM)

CCCC-243.7%

USBCN/A

Net Income (TTM)

CCCC$-101M

USBC$-86M

FCF (TTM)

CCCC$-85M

USBC$-23M

EPS (TTM)

CCCC-$0.78

USBC-$0.22

ROE (TTM)

CCCC-4545.0%

USBC-12093.0%

ROA (TTM)

CCCC-3090.0%

USBC-9639.0%

ROIC (TTM)

CCCC-4545.0%

USBC-11297.0%

Cash

CCCC$79M

USBC$3M

Debt

CCCC$0

USBC$15M

Net Cash/Debt

CCCC$79M

USBC$-12M

Current Ratio (TTM)

CCCC5.45x

USBC0.23x

Quick Ratio (TTM)

CCCC5.29x

USBC0.20x

Debt/Equity (TTM)

CCCC0.00x

USBC0.32x

Debt/Assets (TTM)

CCCC0.0%

USBC0.0%

Interest Coverage (TTM)

CCCCN/A

USBCN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

USBC0.00x

Beta

CCCC3.16

USBC2.77

52W Performance

CCCC41.7%

USBC-51.9%

YTD Performance

CCCC63.7%

USBC-22.2%

% from 52W High

CCCC-38.9%

USBC-60.5%

% from 52W Low

CCCC87.0%

USBC78.7%

Asset Turnover (TTM)

CCCC0.11x

USBC0.00x

FCF Yield (TTM)

CCCC-24.4%

USBC-11.6%

Earnings Yield (TTM)

CCCC-29.0%

USBC-43.5%

Dividend Yield (TTM)

CCCCN/A

USBCN/A

Rule of 40

CCCC-241.4

USBC0.0

EV/GP/RG

CCCCN/A

USBCN/A

Ticker research

View CCCC research View USBC research

Metric	CCCC C4 Therapeutics, Inc	USBC USBC Inc
Market & Valuation
Market Cap	$349M	$198M
Enterprise Value	$271M	$210M
Price	$3.16	$0.51
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	0.00x
EV/Sales	7.73x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	4.46x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-9.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	2.3%	N/A
Forward Rev Growth	-15.9%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	0.0%
Net Margin (TTM)	-289.4%	0.0%
FCF Margin (TTM)	-243.7%	N/A
Net Income (TTM)	$-101M	$-86M
FCF (TTM)	$-85M	$-23M
EPS (TTM)	-$0.78	-$0.22
ROE (TTM)	-4545.0%	-12093.0%
ROA (TTM)	-3090.0%	-9639.0%
ROIC (TTM)	-4545.0%	-11297.0%
Financial Health
Cash	$79M	$3M
Debt	$0	$15M
Net Cash/Debt	$79M	$-12M
Current Ratio (TTM)	5.45x	0.23x
Quick Ratio (TTM)	5.29x	0.20x
Debt/Equity (TTM)	0.00x	0.32x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	2.77
52W Performance	41.7%	-51.9%
YTD Performance	63.7%	-22.2%
% from 52W High	-38.9%	-60.5%
% from 52W Low	87.0%	78.7%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-24.4%	-11.6%
Earnings Yield (TTM)	-29.0%	-43.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View USBC research